The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii

Journal of Infection

Volumn 63, Issue 5, 2011, Pages 351-361

  Ye, Jung Jr ^a   Lin, Huang Shen ^b   Kuo, An Jing ^b,c   Leu, Hsieh Shong ^a   Chiang, Ping Cherng ^a   Huang, Ching Tai ^a   Lee, Ming Hsun ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Acinetobacter baumannii; Multidrug resistant; Pneumonia; Tigecycline

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; TIGECYCLINE;

ACINETOBACTER INFECTION; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; DEMOGRAPHY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, BACTERIAL; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 80054089411     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.08.001     Document Type: Article

References (27)

1. Hsueh P.R., Teng L.J., Chen C.Y., Chen W.H., Yu C.J., Ho S.W., et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002, 8:827-832.
2. Playford E.G., Craig J.C., Iredell J.R. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007, 65:204-211.
3. Sunenshine R.H., Wright M.O., Maragakis L.L., Harris A.D., Song X., Hebden J., et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13:97-103.
4. Ye J.J., Huang C.T., Shie S.S., Huang P.Y., Su L.H., Chiu C.H., et al. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS ONE 2010, 5(4):e9947. doi:10.1371/journal.pone.0009947.
5. Giamarellou H., Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options?. Drugs 2009, 69:1879-1901.
6. Hoban D.J., Bouchillon S.K., Johnson B.M., Johnson J.L., Dowzicky M.J. In vitro activity of tigecycline against 6,792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005, 52:215-227.
7. Curcio D., Fernández F., Cané A., Barcelona L., Stamboulian D. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 2008, 12:198-201.
8. FDA Drug Safety Communication. Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available at: [accessed September, 2010]. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm.
9. Freire A.T., Melnyk V., Kim M.J., Datsenko O., Dzyublik O., Glumcher F., et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010, 68:140-151.
10. Pichardo C., Pachón-Ibañez M.E., Docobo-Perez F., López-Rojas R., Jiménez-Mejías M.E., Garcia-Curiel A., et al. Efficacy of tigecycline vs. imipenem in the treatment of experimental Acinetobacter baumannii murine pneumonia. Eur J Clin Microbiol Infect Dis 2010, 29:527-531.
11. Curcio D., Fernández F., Vergara J., Vazquez W., Luna C.M. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009, 21:58-62.
12. Schafer J.J., Goff D.A., Stevenson K.B., Mangino J.E. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacother 2007, 27:980-987.
13. Poulakou G., Kontopidou F.V., Paramythiotou E., Kompoti M., Katsiari M., Mainas E., et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009, 58:273-284.
14. Gordon N.C., Wareham D.W. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009, 63:775-780.
15. Anthony K.B., Fishman N.O., Linkin D.R., Gasink L.B., Edelstein P.H., Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin Infect Dis 2008, 46:567-570.
16. Peleg A.Y., Potoski B.A., Rea R., Adams J., Sethi J., Capitano B., et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007, 59:128-131.
17. Schreckenberger P.C., Daneshvar M.I., Weyant R.S., Hollis D.G. Acinetobacter, Achromobacter, Chryseobacerium, Moraxella and other nonfermentative gram-negative rods. Manual of clinical microbiology 2005, 749-779. American Society of Microbiology, Washington, DC. 8th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.A. Pfaller, R.H. Yolken (Eds.).
18. Performance standards for antimicrobial disk susceptibility tests 2008, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA, USA, pp. M2-A9. 9th ed.
19. Jones R.N., Ferraro M.J., Reller L.B., Schreckenberger P.C., Swenson J.M., Sader H.S. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 2007, 45:227-230.
20. Paterson D.L. The Epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006, 43(Suppl. 2):S43-S48.
21. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society.
22. Fujitani S., Cohen-Melamed M.H., Tuttle R.P., Delgado E., Taira Y., Darby J.M. Comparison of semi-quantitative endotracheal aspirates to quantitative non-bronchoscopic bronchoalveolar lavage in diagnosing ventilator-associated pneumonia. Respir Care 2009, 54:1446-1448.
23. Petersen P.J., Labthavikul P., Jones C.H., Bradford P.A. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006, 57:573-576.
24. Sands M., McCarter Y., Sanchez W. Synergy testing of multidrug resistant Acinetobacter baumanii against tigecycline and polymyxin using an E-test methodology. Eur J Clin Microbiol Infect Dis 2007, 26:521-522.
25. Scheetz M.H., Qi C., Warren J.R., Postelnick M.J., Zembower T., Obias A., et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007, 51:1621-1626.
26. Yahav D., Lador A., Paul M., Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011, doi: 10.1093/jac/dkr242.
27. Meagher A.K., Ambrose P.G., Grasela T.H., Ellis-Grosse E.J. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005, 52:165-171.